Figure 4.
Myricetin enhances the efficacy of paclitaxel in ovarian cancer cells by targeting MDR-1. (A and B) Cultured A2780 and OVCAR3 cells were treated with 5 µM myricetin for 48 h, and then treated with 100 nM paclitaxel for a further 48 h. Cell viability was assessed using an MTT assay. (C) The effect of myricetin on MDR-1 expression in A2780 and OVCAR3 cells. MYR, myricetin; PTX, paclitaxel; MDR-1, multidrug resistance protein 1.